ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neurological Biomarkers
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1615457
This article is part of the Research TopicBlood, Cerebrospinal Fluid, and Vascular Biomarkers for DementiaView all 18 articles
Synergistic effects of surface-enhanced Raman spectroscopy and enzyme-linked immunoassays in diagnosis of Alzheimer's disease, mild cognitive impairment, and late-life depression
Provisionally accepted
- 1Affiliated Kangning Hospital of Ningbo University, Ningbo, China
- 2Ningbo University, Ningbo, Zhejiang Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Objective tests that can be used to identify neurodegenerative diseases and neuropsychiatric disorders are urgently needed. The primary objective of this study is to evaluate the diagnostic accuracy of Surface-Enhanced Raman Spectroscopy (SERS), a novel blood-based detection method, in differentiating neurodegenerative diseases and neuropsychiatric disorders. Additionally, we aim to assess the synergistic diagnostic performance of combining SERS with Enzyme-Linked Immunosorbent Assay (ELISA) technology for Alzheimer's disease (AD), mild cognitive impairment (MCI), and late-life depression (LLD).In total, 23 patients with AD, 24 with MCI, 20 with LLD, and 20 cognitively normal (control) individuals were enrolled. ELISA and SERS were used to test various biomarkers in the AD, MCI, LLD, and control groups.Results: Amyloid-β, tau, brain-derived neurotrophic factor, proinflammatory cytokine IL-1β, and growth differentiation factor-15 levels as measured using ELISA significantly differed among the four groups (P<0.05). SERS peaks at 592 (P=0.038), 725 (P=0.001), 1003 (P=0.010), 1331 (P=0.000), and 165 cm -1 (P=0.000) likewise significantly differed among the four groups. The area under the curve was significantly higher after combining multiple blood indicators than that with single-blood indicators.Combining SERS and ELISA can significantly increase diagnostic accuracy for AD, MCI and LLD. The findings are expected to provide potential therapeutic targets for precise intervention in these diseases, thereby contributing to improved clinical stratification and personalized treatment strategies.
Keywords: Alzheimer's disease, Mild Cognitive Impairment, late-life depression, Enzyme-Linked Immunosorbent Assay, surface-enhanced Raman spectroscopy
Received: 28 Apr 2025; Accepted: 09 Jun 2025.
Copyright: © 2025 Mei, Zhao, Wang, Qiu, Li, Xiong, Zhu and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xi Mei, Affiliated Kangning Hospital of Ningbo University, Ningbo, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.